{"id":22056,"date":"2025-10-30T16:33:12","date_gmt":"2025-10-30T16:33:12","guid":{"rendered":"http:\/\/tezgyan.com\/index.php\/2025\/10\/30\/cipla-q2-results-net-profit-rises-3-7-to-rs-1353-crore-achin-gupta-to-become-md-global-ceo-business-news\/"},"modified":"2025-10-30T16:33:12","modified_gmt":"2025-10-30T16:33:12","slug":"cipla-q2-results-net-profit-rises-3-7-to-rs-1353-crore-achin-gupta-to-become-md-global-ceo-business-news","status":"publish","type":"post","link":"https:\/\/tezgyan.com\/index.php\/2025\/10\/30\/cipla-q2-results-net-profit-rises-3-7-to-rs-1353-crore-achin-gupta-to-become-md-global-ceo-business-news\/","title":{"rendered":"Cipla Q2 Results: Net Profit Rises 3.7% To Rs 1,353 Crore; Achin Gupta To Become MD & Global CEO | Business News"},"content":{"rendered":"


\n<\/p>\n

\n

Last Updated:<\/span>

Cipla Q2 Results: Its revenue from operations in July-September 2025 rises 7.64% to Rs 7,589.44 crore, compared with Rs 7,051.02 crore in the year-ago period.<\/h2>\n
\"Cipla<\/p>\n

Cipla Q2 Results.<\/p>\n<\/figure>\n

Cipla Q2 Results:<\/strong> Pharma company Cipla Ltd on Thursday reported a 3.7 per cent rise in its consolidated net profit to Rs 1,353.37 crore for the second quarter ended September 30, 2025. Its revenue from operations in July-September 2025 rose 7.64% to Rs 7,589.44 crore, compared with Rs 7,051.02 crore in the year-ago period.<\/p>\n

The net profit had stood at Rs 1,305.01 crore in the corresponding period last year, according to a regulatory filing.<\/p>\n

Cipla said its managing director & Global CEO Umang Vohra has decided not to seek re-appointment upon completion of his current term on March 31, 2026. Subsequently, Achin Gupta, global chief operating officer of Cipla, has been elevated and appointed as its managing director & global chief executive officer with effect from April 1, 2026, for a term of five years up to March 31, 2031.<\/p>\n

Its total expenses in Q2FY26 rose to Rs 6,004.86 crore, compared with Rs 5,452.57 crore in the corresponding period last fiscal, the company said.<\/p>\n

In the second quarter, the pharmaceuticals segment recorded revenue of Rs 7,291.43 crore, up from Rs 6,775.56 crore in the same period a year ago.<\/p>\n

New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.<\/p>\n

\u201cIn Q2FY26, we delivered our highest-ever quarterly revenue of Rs 7,589 crore, with a robust EBITDA margin of 25 per cent. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets,” Vohra said.<\/p>\n

The company\u2019s \u2018One-India business\u2019 grew by 7 per cent year-on-year, while trade generics recorded double-digit growth, and the anchor brands of the consumer health business maintained a leadership position, he noted.<\/p>\n

\u201cWith a positive traction in our differentiated assets, the US business posted a revenue of $233 million during the quarter,” he added.<\/p>\n

On \u2018One Africa\u2019, Vohra said, \u201cWe achieved a healthy growth of 5 per cent YoY in dollar terms. Emerging Markets and Europe delivered a solid revenue growth of 15 per cent YoY in dollar terms on the back of a deep market focus strategy.” Going ahead, he said, \u201cThe focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”<\/p>\n

(With PTI Inputs)<\/em><\/strong><\/p>\n

\n
\n
<\/p>\n
\"Mohammad<\/figure>\n

<\/span><\/p>\n

Mohammad Haris<\/a><\/p>\n

Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h…Read More<\/span><\/p>\n<\/div>\n<\/div>\n

Haris is Deputy News Editor (Business) at news18.com. He writes on various issues related to personal finance, markets, economy and companies. Having over a decade of experience in financial journalism, Haris h… Read More<\/span><\/p>\n<\/div>\n<\/div>\n

Follow News18 on Google<\/a>. Join the fun, play QIK games on News18<\/a>. Stay updated with all the latest business news, including market trends<\/a>,\u00a0stock updates<\/a>,\u00a0tax<\/a>, IPO,\u00a0banking finance<\/a>, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the\u00a0News18 App<\/a> to stay updated.<\/span><\/div>\n
First Published:<\/span><\/p>\n
\n

October 30, 2025, 15:18 IST<\/p>\n<\/div>\n<\/div>\n

News<\/a> business<\/a> Cipla Q2 Results: Net Profit Rises 3.7% To Rs 1,353 Crore; Achin Gupta To Become MD & Global CEO<\/span><\/div>\n
\n
\n
Disclaimer: Comments reflect users\u2019 views, not News18\u2019s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use<\/a> and Privacy Policy<\/a>.<\/div>\n<\/div>\n<\/div>\n

Read More<\/span><\/p>\n<\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Last Updated:October 30, 2025, 15:18 IST Cipla Q2 Results: Its revenue from operations in July-September 2025 rises 7.64% to Rs 7,589.44 crore, compared with Rs 7,051.02 crore in the year-ago period. Cipla Q2 Results. Cipla Q2 Results: Pharma company Cipla Ltd on Thursday reported a 3.7 per cent rise in its consolidated net profit to…<\/p>\n","protected":false},"author":1,"featured_media":22057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[],"class_list":["post-22056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"_links":{"self":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/22056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/comments?post=22056"}],"version-history":[{"count":0,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/posts\/22056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media\/22057"}],"wp:attachment":[{"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/media?parent=22056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/categories?post=22056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tezgyan.com\/index.php\/wp-json\/wp\/v2\/tags?post=22056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}